Impax Payment Was Meant To Dodge Competition, FTC Says

Drugmaker Impax Laboratories Inc. accepted an illegal payment from Endo Pharmaceuticals Inc. in exchange for delaying the market entry of Impax’s generic form of Endo’s opioid pain medication Opana ER, the U.S. Federal Trade Commission said Friday…

Read this piece in its entirety at Law360.

Tivity Atty’s ‘Suspicious Stock Sales’ Support Suit, Judge Says

Fitness and wellness program provider Tivity Health lost a bid to kill a stock-drop suit on Monday when a Tennessee federal judge said allegations of “suspicious stock sales” by executives, including Tivity’s chief legal officer, bolstered the case against the company…

Read this piece in its entirety at Law360.


Pharma Co. Pumped Stock By Hiding Drug Failures, Suit Says

A proposed class of investors hit Corbus Pharmaceutical Holdings Inc. and two of its top executives with a securities suit in Massachusetts federal court Tuesday alleging that the company and its officers concealed negative results in clinical trials of its flagship drug…

Read this piece in its entirety at Law360.